Efficacy of Magnesium Sulfate on Reducing Renal Colic in the Emergency Department
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age >18 years old and <100 years old.
- Patients seen in the Emergency Department at Henry Ford Macomb hospital.
- Patients that are A+Ox3.
- Patients who have typical presentation for renal colic.
Exclusion Criteria:
- Age <18 years.
- Patients with a history of dementia, acute delirium or altered mental status.
- Patients with inability to consent to study or inability to fill questionnaire independently.
- Patients with chronic kidney disease and allergies to study drugs.
- Patients that are pregnant (women who are of child-bearing potential will be screened with a urine BHCG).
- Patients with stroke activation or symptoms.
- Patients with trauma activations.
- Patients over the age of 100 years old are excluded as they make up a small percentage of the population and may become identifiable because of their age.
- Imaging study does not show evidence of ureteral stone.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Treatment
Receiving Magnesium Sulfate
|
|
|
Placebo Comparator: Placebo
Receiving Dextrose 5% in Water (D5W)
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pain Score Change
Time Frame: 1 hour after the completion of treatment medication (Placebo or Study Drug)
|
We asked the patient's pain score on a scale of 0-10 with 10 being the highest amount of pain and 0 no pain, before and after treatment (approximately 1 hour).
Primary Outcome was the change in score before and after treatment.
|
1 hour after the completion of treatment medication (Placebo or Study Drug)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of Participants Requiring Opiates for Additional Pain Control
Time Frame: Any opiate administration required after re-evaluation of pain score after initial treatment with either placebo or study drug
|
We analyzed how many patients required additional pain control with opiates between the two treatment groups.
|
Any opiate administration required after re-evaluation of pain score after initial treatment with either placebo or study drug
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Pain
- Neurologic Manifestations
- Disease Attributes
- Infant, Newborn, Diseases
- Renal Colic
- Emergencies
- Colic
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Anesthetics
- Membrane Transport Modulators
- Anticonvulsants
- Calcium-Regulating Hormones and Agents
- Reproductive Control Agents
- Calcium Channel Blockers
- Tocolytic Agents
- Magnesium Sulfate
Other Study ID Numbers
Other Study ID Numbers
- 10080 (DAIDS ES Registry Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.